Roth Capital analyst Jotin Marango maintained a Hold rating on Savara Inc (NASDAQ: SVRA) today and set a price target of $12. The company’s shares closed on Friday at $11.14.
According to TipRanks.com, Marango is a 4-star analyst with an average return of 18.5% and a 47.2% success rate. Marango covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Stemline Therapeutics Inc, and Actinium Pharmaceuticals.
Savara Inc has an analyst consensus of Strong Buy, with a price target consensus of $23.20.
See today’s analyst top recommended stocks >>
Based on Savara Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $11.59 million. In comparison, last year the company had a GAAP net loss of $11.5 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.
